Form 4: Haemonetics Corp Executive Anila Lingamneni Reports Stock Transaction
SEC Form 4 Filing
Anila Lingamneni, EVP and Chief Technology Officer of Haemonetics Corp, reports disposition of shares to cover tax obligations related to vesting restricted stock units.
Summary
- On April 15, 2024, Anila Lingamneni, EVP and Chief Technology Officer of Haemonetics Corp, disposed of 184 shares of common stock to cover tax obligations.
- The shares were withheld at a price of $84.88 per share.
- Following the transaction, Lingamneni directly owns 14,311 shares of Haemonetics Corp, which includes unvested Restricted Stock Units (RSUs).
Sentiment
Score: 5
Explanation: Neutral sentiment as the filing reflects a routine transaction related to executive compensation and tax obligations.
Industry Context
Form 4 filings are a routine part of corporate governance, providing transparency into the transactions of company insiders. This transaction is related to tax obligations from vested RSUs, a common form of executive compensation.
Stakeholder Impact
- The transaction has a minimal impact on stakeholders as it is a routine sale of shares to cover tax obligations.
Key Dates
| Date | Description |
|---|---|
| 04/15/2024 | Date of stock transaction (disposal of shares). |
| 04/17/2024 | Date of signature on the Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.